Intellectual Property Protection for Tetra Discovery Partners’ BPN14770 Boosted with Issuance of New U.S. Patent

Grand Rapids, MI (October 11, 2018): Tetra Discovery Partners today announced that the U.S. Patent and Trademark Office has issued a third patent covering the company’s selective phosphodiesterase-4D (PDE4D) inhibitor, BPN 14770, and related compounds. The new patent, US 10,093,686, covers claims for the use such compounds in the treatment of mild cognitive impairment, Parkinson’s disease, stroke and ischemia. “This new patent further builds on the intellectual property protections for our lead compound, adding to the previously issued patents covering BPN 14770’s composition and use in the treatment of Alzheimer’s disease,” said Mark Gurney, Ph.D., Chairman and Chief Executive Officer of Tetra. “We believe this compound has the potential to benefit the lives of many patients with cognitive disorders, Alzheimer’s disease, and related illnesses.” “We are pleased to add this patent to the growing Worldwide IP portfolio covering this exciting new compound,” said Chad Coberly, JD, Senior Vice President, Clinical, Regulatory & Legal Affairs at Tetra. “Related patents have now issued in Japan, China, and Israel and prosecution continues in Europe and in several other potentially significant markets for the new therapy.”About BPN14770 BPN14770 is a novel therapeutic agent that selectively inhibits phosphodiesterase-4D (PDE4D) to enhance early and late stages of memory formation. This unique mechanism of action has the potential to improve cognitive and memory function in devastating disorders including Fragile X Syndrome, Alzheimer’s disease and other dementias, learning/developmental disabilities and schizophrenia. Tetra Discovery has initiated an investigational Phase 2 study of BPN14770 in adults with Fragile X Syndrome, an indication for which BPN14770 has received Orphan Drug Designation from the U.S. Food and Drug Administration. Preparations are also under way to initiate a Phase 2 trial of BPN14770 in patients with Alzheimer’s disease. BPN14770 is currently approved for investigational use only by the U.S. Food and Drug Administration and is not currently approved for marketing in any territory. About Tetra Discovery Partners Tetra Discovery Partners is a clinical stage biotechnology company developing a portfolio of therapeutic products that will bring clarity of thought to people suffering from neuro-developmental conditions such as Fragile X Syndrome, Alzheimer’s disease, traumatic brain injury, and other brain disorders. Tetra uses structure-guided drug design to discover mechanistically novel, allosteric inhibitors of phosphodiesterase 4 (PDE4), an enzyme family that plays key roles in memory formation, learning, neuroinflammation, and traumatic brain injury. Tetra Discovery Partners is headquartered in Grand Rapids, Michigan. For more information, please visit the company’s website at http://www.tetradiscovery.com. Forward looking Statements Certain other statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company’s future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.###

Contact: Mark Gurney, Ph.D., Chief Executive Officer Tetra Discovery Partners info@tetradiscovery.com For Media: Joan Kureczka Bioscribe, Inc. Joan@bioscribe.com (415) 821-2413